IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
09 janv. 2025 08h05 HE
|
IO Biotech
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical...
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank
20 déc. 2024 08h05 HE
|
IO Biotech
Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in 2025Commitment is part of the European Investment...
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
12 nov. 2024 07h05 HE
|
IO Biotech
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
IO Biotech Announces Participation in Upcoming Investor Conferences
11 nov. 2024 16h05 HE
|
IO Biotech
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
07 nov. 2024 10h00 HE
|
IO Biotech
-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response rate...
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
04 oct. 2024 09h00 HE
|
IO Biotech
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based...
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
14 sept. 2024 02h30 HE
|
IO Biotech
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals...
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
30 août 2024 16h05 HE
|
IO Biotech
- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety...
IO Biotech Announces Participation in Upcoming Investor Conferences
26 août 2024 16h05 HE
|
IO Biotech
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
13 août 2024 07h05 HE
|
IO Biotech
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights